ABSORB's biggest benefit is that it eliminates the risk of late stent thrombosis and obviates the need to take antiplatelet drugs for years (which means forever for some patients).
However, ABSORB is harder to implant than XIENCE (ABT's market-leading conventional stent), so there's a long-term vs short-term tradeoff that doctors and patients need to make.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.